Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
CONCLUSIONS: Considering in vitro and available clinical data, desvenlafaxine and venlafaxine appear to have low potential for pharmacokinetic drug-drug interactions via inhibiting the metabolic clearance of concomitant drugs that are substrates of various CYP enzymes, in particular CYP2D6. In addition, these data suggest that desvenlafaxine and venlafaxine exhibit little potential for pharmacokinetic interactions with concomitant drugs that are substrates or inhibitors of P-gp.
PMID: 19629022 [PubMed - indexed for MEDLINE] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 5, 2015 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
CONCLUSIONS: Shortterm desvenlafaxine therapy (50 to 400 mg/d) improved a broad range of emotional and physical symptoms in outpatients with MDD.
PMID: 19752839 [PubMed - indexed for MEDLINE] (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - June 5, 2015 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research
Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
CONCLUSIONS: Steady-state desvenlafaxine 100 mg did not affect tamoxifen pharmacokinetics. For women treated with tamoxifen, desvenlafaxine may represent a safe and effective treatment unlikely to alter tamoxifen efficacy.
PMID: 25138680 [PubMed - in process] (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - June 4, 2015 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Antidepressant induced excessive yawning and indifference
Conclusion Induction of indifference and excessive yawning may be modulated by serotonergic and noradrenergic mechanisms. One proposal to unify these side effects would be enhancement of serotonin in midbrain, especially paraventricular and raphe nucleus. Introdução Alguns relatos de caso descrevem pacientes com bocejos excessivos induzidos por antidepressivos. Também é relatada a capacidade dos antidepressivos induzirem uma síndrome de indiferença. A frequência desses efeitos colaterais é desconhecida, assim como seus mecanismos fisiopatológicos. Ambos os efeitos são considerados benignos e costumam ser revers...
Source: Jornal Brasileiro de Psiquiatria - May 16, 2015 Category: Psychiatry Source Type: research
Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression: A Meta-Analysis
Discussion: Antidepressants are associated with different insomnia and somnolence rates, mainly depending on their mechanisms of action. Despite some limitations, we underscore that the treatment-emergent insomnia and/or somnolence are frequent, and they could be used in clinical practice to face the specific needs of each patient. (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - May 1, 2015 Category: Psychiatry Tags: Review Articles Source Type: research
Estimating the cost-effectiveness of Vortioxetine versus Desvenlafaxine as first line Therapy for mild to moderate Major depressive Disorder in remitted patients
The primary objective was to estimate incremental cost-effectiveness of vortioxetine, a serotonin modulator and simulator (SMS) versus desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), as potential first line medications for treatment of mild or moderate major depression. The clinical benefit of a SMS may be in faster onset and shorter time to remission. Evidence suggests vortioxetine causes fewer adverse drug events (ADEs) than desvenlafaxine, which has implications for discontinuation of therapy. (Source: Value in Health)
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: K.R. Keyloun, B. Devine Source Type: research
Nonhormonal strategies for hot flushes
A wide choice is available for women who do not wish to use estrogen. Paroxetine, fluoxetine, citalopram, venlafaxine and desvenlafaxine have been found to be effective in several studies. In 2013 the U.S. Food and Drug Administration approved paroxetine to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Clonidine is a centrally acting alpha-adrenoceptor agonist that was developed originally for the treatment of hypertension. It is licensed for the treatment of hot flushes in some countries. (Source: Maturitas)
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Margaret Rees Tags: INV2 Source Type: research
Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis
Current Medical Research & Opinion, Ahead of Print. (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 26, 2015 Category: Research Tags: article Source Type: research
An evaluation of salt screening methodologies
ConclusionsThe three salt formation approaches are methods that deliver crystalline salts. The choice of salt screen approach depends on the physical properties of the drug substance, development stage and objective of the screen. (Source: Journal of Pharmacy and Pharmacology)
Source: Journal of Pharmacy and Pharmacology - February 14, 2015 Category: Drugs & Pharmacology Authors: Ana Fernández Casares, W. Mieke Nap, Glòria Ten Figás, Pieter Huizenga, Richard Groot, Marcel Hoffmann Tags: Research Paper Source Type: research
Research Roundup
Ten years after FDA warning and product labeling, glucose screening with SGAs still lags
Desvenlafaxine found safe for youth with MDD in exploratory open‐label trial (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - December 23, 2014 Category: Psychiatry Tags: Research Roundup Source Type: research
Effect of redox conditions on pharmaceutical loss during biological wastewater treatment using sequencing batch reactors
In this study, the fate of a mixture of pharmaceuticals and several of their transformation products present in the primary effluent of a local WWTP was assessed in sequencing batch reactors operated under different redox conditions: fully aerobic, anoxic/aerobic, and microaerobic (DO concentration ≈0.3mg/L). Among the pharmaceuticals that were tracked during this study (atenolol, trimethoprim, sulfamethoxazole, desvenlafaxine, venlafaxine, and phenytoin), overall loss varied between them and between redox environments. Losses of atenolol and trimethoprim were highest in the aerobic reactor; sulfamethoxazole loss was hig...
Source: Journal of Hazardous Materials - November 21, 2014 Category: Environmental Health Source Type: research
In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor
Publication date: January 2015 Source:Physiology & Behavior, Volume 138 Author(s): Jian Hou , Yanli Xing , Daiying Zuo , Yingliang Wu , Jingwei Tian , Qingguo Meng , Mina Yang Triple reuptake inhibitors (TRIs) that inhibit the reuptake of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) are being developed as a new class of antidepressants, which is hypothesized to produce more rapid onset and better efficacy than conventional antidepressants in part due to the addition of the DA component. 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)-ethyl]-phenyl benzoate hydrochloride (PA01), a novel compound,...
Source: Physiology and Behavior - November 14, 2014 Category: Physiology Source Type: research
Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.
CONCLUSIONS: These results support previous findings demonstrating antidepressant efficacy, safety, and tolerability of desvenlafaxine 50 and 100 mg/d versus placebo. Sexual function was comparable between desvenlafaxine and placebo.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01432457.
PMID: 25375652 [PubMed - as supplied by publisher] (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - November 12, 2014 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
Desvenlafaxine reduces apoptosis in amygdala after myocardial infarction.
This study was designed to determine if desvenlafaxine (DV), a serotonin-norepinephrine reuptake inhibitor, can attenuate apoptosis observed in the limbic system after myocardial infarction (MI). MI was induced in rats by occlusion of the left descending artery for 40min followed by reperfusion. Another group of sham (control) rats was similarly manipulated, but without occlusion. Half of the full cohort received DV (3mg/kg/day intraperitoneal), starting 5min after the onset of reperfusion; the other half received the vehicle (0.5ml of 0.9% saline). Rats were sacrificed after 3 days for biochemical analyses and MI size mea...
Source: Brain Research Bulletin - November 6, 2014 Category: Neurology Authors: Malick M, Gilbert K, Barry M, Godbout R, Rousseau G Tags: Brain Res Bull Source Type: research
Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: Focus on children, adolescents and prescriber specialty
Conclusions:
Dispensing of psychotropic medications increased markedly from 2009 to 2012, with notable age-specific trends. General adherence to treatment guidelines is apparent, yet concerns exist regarding rapid increases in serotonin noradrenaline reuptake inhibitor (SNRI) antidepressant prescribing, the likely overmedication of persons with mild psychological distress, and the increasing use of powerful psychotropic medications in younger populations despite uncertain risk–benefit profiles. (Source: Australian and New Zealand Journal of Psychiatry)
Source: Australian and New Zealand Journal of Psychiatry - September 25, 2014 Category: Psychiatry Authors: Karanges, E. A., Stephenson, C. P., McGregor, I. S. Tags: Research Source Type: research
